# Medicare

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/medicare-product
Canonical HTML page: https://getfinancebrief.com/entity/medicare-product

## Timeline

- **2027-01-01**: Price Cut Effective — Novo Nordisk's 50% list price reduction for Ozempic and Wegovy takes effect.
- **2026-01-01**: Negotiation Deadline — Expected announcement of final negotiated prices for the first round of Medicare drugs.
- **2024-09-24**: Senate Hearing — Novo Nordisk CEO Lars Fruergaard Jørgensen testifies on high U.S. drug prices.
- **2022-08-16**: IRA Signed — Inflation Reduction Act grants CMS authority to negotiate drug prices.

## Recent coverage (1 stories)

### Novo Nordisk to Slash Ozempic and Wegovy List Prices by 50% in 2027
2026-02-24 20:16:02 · Sentiment: Bullish · Impact: 8/10 · Sources: 2

Novo Nordisk has announced a significant reduction in the list prices for its blockbuster GLP-1 drugs, Ozempic and Wegovy, effective in 2027. The move, which could see prices drop by up to 50%, comes amid intense political pressure and federal negotiations aimed at lowering healthcare costs for American consumers.
Full story: https://getfinancebrief.com/story/novo-nordisk-ozempic-wegovy-price-cuts-2027

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.